Summary & Overview

HCPCS G9837: Trastuzumab Not Administered Within 12 Months

HCPCS Level II code G9837 documents when trastuzumab is not administered within 12 months of a qualifying cancer diagnosis. The code captures a specific clinical gap in the delivery of HER2-directed therapy and is used for tracking treatment adherence, quality measurement, and downstream administrative processes. Nationally, such a code matters because trastuzumab is a standard-of-care agent for HER2-positive cancers; documenting its omission within the first year has implications for quality reporting, care coordination, and contractual performance measures.

This analysis covers major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the service context and typical sites of service, and the types of benchmarks and policy-relevant issues tied to nonadministration of trastuzumab. The publication summarizes how payers commonly treat documentation of treatment gaps and what administrative data elements are relevant for claims and quality monitoring.

The report does not provide clinical recommendations. It provides operational and policy-focused information: code definition and use, payer scope, typical service settings, and where to look for related billing and quality measure guidance. Data not available in the input are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9837HCPCS Level IItrastuzumaboncologyinfusionquality-measuretreatment-gapher2-positiveclaims-coding

Billing Code Overview

HCPCS Level II code G9837 denotes trastuzumab not administered within 12 months of diagnosis. This code documents the absence of trastuzumab (a HER2-targeted therapy) within the first year following a qualifying cancer diagnosis.

Service type: Oncology therapeutic administration gap documentation
Typical site of service: Oncology clinic or hospital outpatient infusion center

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 58-year-old female patient diagnosed with HER2-positive invasive breast carcinoma 14 months ago presents for oncology follow-up. Initial staging and treatment planning included surgery and chemotherapy, but adjuvant trastuzumab (HER2-targeted monoclonal antibody) was not administered within 12 months of diagnosis due to pregnancy and subsequent cardiac comorbidity that delayed infusions. At this visit, the oncology team documents the reason trastuzumab was not started within 12 months and assesses current disease status, cardiac function (echocardiogram), and eligibility for late initiation or alternative HER2-directed therapy. The clinical workflow includes chart review of prior treatments and dates, verification of HER2 status, documenting the exception reason in the medical record, communicating with the infusion center and payer for coverage determination, and coding the encounter with the HCPCS Level II code G9837 to indicate trastuzumab not administered within 12 months of diagnosis. Typical sites of service are outpatient oncology clinics and infusion centers. Usual care team members include a medical oncologist, oncology nurse, pharmacist, and clinic administrative staff coordinating prior authorization and scheduling.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when services require substantially greater effort or complexity than typical, e.g., extensive documentation for delayed trastuzumab initiation due to complex comorbidity management.
`23`	Unusual anesthesia	Rarely applicable but used if unusual anesthesia is required for a diagnostic procedure tied to treatment timing decisions.
`52`	Reduced services	Use when planned treatment or service is partially reduced or omitted, for example if an infusion session is abbreviated.
`53`	Discontinued procedure	Use when a procedure to deliver therapy is started but then stopped prior to completion for patient safety reasons.
`54`	Surgical care only	Not commonly used directly with this code; applicable when surgical team bills separately from oncologic medical management.
`55`	Postoperative management only	Use when only postoperative care is billed by the surgeon and oncologic management is billed by oncology.
`56`	Preoperative management only	Use when only preoperative evaluation is billed separately from other services affecting treatment timing.
`62`	Two surgeons	Use if two distinct surgeons are involved in a complex operative case that influences timing of adjuvant therapy.
`AS`	Non‑physician assistant	Use when a surgical assistant who is not a physician provides assistance during procedures affecting treatment schedule.
`QX`	Service furnished under a qualified non‑physician practitioner	Use when parts of the evaluation or infusion management are provided under a supervising physician by a qualified non‑physician practitioner.

Taxonomy Code	Specialty	Notes
`207RG0100X`	Medical Oncology	Primary specialty managing trastuzumab timing and systemic therapy decisions.
`207RH0000X`	Hematology/Oncology	Often involved when multidisciplinary oncologic management and chemotherapy planning are required.
`2085R0201X`	Oncology Nursing	Clinic and infusion nursing staff who administer therapy and document delays or exceptions.
`366A00000X`	Pharmacy	Oncology pharmacists review biologic therapy eligibility, dosing, and prior authorization requirements.
`207L00000X`	Surgical Oncology	Surgeons whose operative timing or complications may affect initiation of adjuvant trastuzumab.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.912`	Malignant neoplasm of unspecified site of left breast	Primary diagnosis for patients eligible for trastuzumab when HER2-positive breast cancer is present; indicates breast cancer requiring systemic therapy.
`C50.911`	Malignant neoplasm of unspecified site of right breast	Same relevance for right-sided disease.
`C50.919`	Malignant neoplasm of unspecified breast, unspecified side	Used when laterality is not specified; indicates breast cancer diagnosis relevant to trastuzumab consideration.
`Z85.3`	Personal history of malignant neoplasm of breast	Used in follow-up and survivorship visits where adjuvant therapy timing and missed opportunities are documented.
`I50.9`	Heart failure, unspecified	Cardiac dysfunction that commonly impacts timing or contraindicates trastuzumab due to cardiotoxicity risk; often assessed before (re)starting therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Used for standard trastuzumab IV infusion sessions when therapy is given after authorization.
`96417`	Chemotherapy administration, each additional hour (List separately in addition to code for primary infusion)	Used when trastuzumab or combination infusions extend beyond the initial hour.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Used for oncology follow-up visits documenting reasons for delayed initiation and treatment planning.
`93306`	Echocardiography, transthoracic, real-time with image documentation (2D), complete, with spectral Doppler and color flow Doppler	Used to assess left ventricular ejection fraction prior to initiation or re-initiation of trastuzumab when cardiac concerns delayed therapy.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Occasionally used if alternative HER2 therapies are delivered via non-intravenous routes as part of treatment planning.